Pfizer’s tofacitinib is likely to be the first oral DMARD to gain FDA approval. Our panel focused extensively on positioning, strengths and weaknesses, and expected pricing for this compound.
Scottsdale, AZ (PRWEB) April 20, 2011
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, with a focus on rheumatoid arthritis (RA).
To develop this analysis, entitled “Thought Leader Insight & Analysis: Rheumatology Q1 2011,” MedPredict conducted primary interviews with U.S.-based and European rheumatology thought leaders. MedPredict has published over 32 research reports in rheumatology and maintains ongoing relationships with experts in North America and Western Europe.
“Pfizer’s tofacitinib is likely to be the first oral DMARD to gain FDA approval,” according to MedPredict president Jeff Berk. “For this report our rheumatology panel focused extensively on positioning, strengths and weaknesses, and expected pricing for this compound and AstraZeneca/Rigel’s fostamatinib,” Other topics covered:
- Any advantages expected in the next generation anti-IL-6 approaches?
- Interest in IL-17 or IL-23 inhibition for RA?
- Likely success of chemokine receptor antagonists (CCR, IP-10/CXCL10) for this indication?
Other mechanisms discussed included: fynomers, immunomodulators, interferon alpha, JAK, p38, Syk, and anti-TNF.
Companies mentioned in this report include: Abbott, Alder, Amgen, AstraZeneca, Bristol-Myers Squibb, Caprecom, Celgene, Centocor, ChemoCentryx, Chugai, Conaris, Covagen, Cytopia, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Incyte, Ligand, Lilly, MedImmune, Merck, Millennium/Takeda, Mycenax Biotech, Novartis, Pfizer, Regeneron, Sanofi-Aventis, Takeda, UCB, Vertex, and YM Biosciences.
This report can be purchased by contacting MedPredict.
MedPredict (http://www.medpredict.com ) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
For more information contact: